Literature DB >> 24744600

Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer.

Yun-Feng Wang1, Fei-Ling Feng1, Xu-Hong Zhao1, Zhen-Xiong Ye1, He-Ping Zeng1, Zhen Li1, Xiao-Qing Jiang1, Zhi-Hai Peng1.   

Abstract

AIM: To clarify the value of combined use of markers for the diagnosis of gallbladder cancer and prediction of its prognosis.
METHODS: Serum cancer antigens (CA)199, CA242, carcinoembryonic antigen (CEA), and CA125 levels were measured in 78 patients with gallbladder cancer (GBC), 78 patients with benign gallbladder diseases, and 78 healthy controls using electrochemiluminescence. CA199, CA242, CEA, and CA125 levels and positive rates were analyzed and evaluated pre- and post-operatively. Receiver operator characteristic curves were used to determine diagnostic sensitivity and specificity of GBC. Survival time analysis, including survival curves, and multivariate survival analysis of a Cox proportional hazards model was performed to evaluate independent prognostic factors.
RESULTS: Serum CA242, CA125, and CA199 levels in the GBC group were significantly higher when compared with those in the benign gallbladder disease and healthy control groups (P < 0.01). With a single tumor marker for GBC diagnosis, the sensitivity of CA199 was the highest (71.7%), with the highest specificity being in CA242 (98.7%). Diagnostic accuracy was highest with a combination of CA199, CA242, and CA125 (69.2%). CA242 could be regarded as a tumor marker of GBC infiltration in the early stage. The sensitivity of CA199 and CA242 increased with progression of GBC and advanced lymph node metastasis (P < 0.05). The 78 GBC patients were followed up for 6-12 mo (mean: 8 mo), during which time serum CA199, CA125, and CA242 levels in the recurrence group were significantly higher than in patients without recurrence (P < 0.01). The post-operative serum CA199, CA125, and CA242 levels in the non-recurrence group were significantly lower than those in the GBC group (P < 0.01). Multivariate survival analysis using a Cox proportional hazards model showed that cancer of the gallbladder neck and CA199 expression level were independent prognostic factors.
CONCLUSION: CA242 is a marker of GBC infiltration in the early stage. CA199 and cancer of the gallbladder neck are therapeutic and prognostic markers.

Entities:  

Keywords:  Combined detection; Diagnosis; Gallbladder cancer; Prognosis; Tumor marker

Mesh:

Substances:

Year:  2014        PMID: 24744600      PMCID: PMC3983467          DOI: 10.3748/wjg.v20.i14.4085

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  38 in total

1.  CA 125: a potential tumor marker for gallbladder cancer.

Authors:  Amita Chaube; Mallika Tewari; Usha Singh; H S Shukla
Journal:  J Surg Oncol       Date:  2006-06-15       Impact factor: 3.454

2.  Bile duct involvement portends poor prognosis in resected gallbladder carcinoma.

Authors:  Robert Eil; Paul D Hansen; Maria Cassera; Susan L Orloff; Brett C Sheppard; Brian Diggs; Kevin G Billingsley
Journal:  Gastrointest Cancer Res       Date:  2013-07

3.  Unsuspected gallbladder cancer: a clinical retrospective study.

Authors:  Liangshuo Hu; Bo Wang; Xuemin Liu; Yi Lv
Journal:  Arch Iran Med       Date:  2013-11       Impact factor: 1.354

4.  Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.

Authors:  Wei-Feng Shen; Wei Zhong; Feng Xu; Tong Kan; Li Geng; Feng Xie; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

5.  Evaluation of CA 242 as a tumor marker in gallbladder cancer.

Authors:  Surinder Rana; Usha Dutta; Rakesh Kochhar; Satyavati V Rana; Rajesh Gupta; Ravinder Pal; Kapil Jain; Radhika Srinivasan; Birender Nagi; Chander Kant Nain; Kartar Singh
Journal:  J Gastrointest Cancer       Date:  2012-06

6.  Diagnosis and cure experience of hepatolithiasis-associated intrahepatic cholangiocarcinoma in 66 patients.

Authors:  Hong-Yang Li; Shi-Ji Zhou; Min Li; Ding Xiong; Akanand Singh; Qing-Xi Guo; Chang-An Liu; Jian-Ping Gong
Journal:  Asian Pac J Cancer Prev       Date:  2012

7.  The evaluation of tumor markers levels in determination of surgical procedure in patients with gallbladder carcinoma.

Authors:  D Stefanović; R Novaković; M Perisić-Savić; Z Djordjević; M Zivanović; S Stajić
Journal:  Med Pregl       Date:  1993

8.  Xanthogranulomatous cholecystitis: a clinicopathological study of its association with gallbladder carcinoma.

Authors:  Peng Yuan Zhuang; Ming Jie Zhu; Jian Dong Wang; Xue Ping Zhou; Zhi Wei Quan; Jun Shen
Journal:  J Dig Dis       Date:  2013-01       Impact factor: 2.325

9.  LAPTM4B allele *2 is a marker of poor prognosis for gallbladder carcinoma.

Authors:  Guojun Zhai; Kaowen Yan; Xiaoxu Ji; Wenrui Xu; Jiuling Yang; Fuxia Xiong; Jing Su; Michael A McNutt; Hua Yang
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

10.  Molecular biology of gallbladder cancer: potential clinical implications.

Authors:  Ake Andrén-Sandberg
Journal:  N Am J Med Sci       Date:  2012-10
View more
  38 in total

1.  Exploring the diagnosis markers for gallbladder cancer based on clinical data.

Authors:  Lingqiang Zhang; Runchen Miao; Xiude Zhang; Wei Chen; Yanyan Zhou; Ruitao Wang; Ruiyao Zhang; Qing Pang; Xinsen Xu; Chang Liu
Journal:  Front Med       Date:  2015-07-15       Impact factor: 4.592

2.  Platelet to lymphocyte ratio as a novel prognostic tool for gallbladder carcinoma.

Authors:  Qing Pang; Ling-Qiang Zhang; Rui-Tao Wang; Jian-Bin Bi; Jing-Yao Zhang; Kai Qu; Su-Shun Liu; Si-Dong Song; Xin-Sen Xu; Zhi-Xin Wang; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

3.  Combination of preoperative NLR, PLR and CEA could increase the diagnostic efficacy for I-III stage CRC.

Authors:  Hong-Xin Peng; Lin Yang; Bang-Shun He; Yu-Qin Pan; Hou-Qun Ying; Hui-Ling Sun; Kang Lin; Xiu-Xiu Hu; Tao Xu; Shu-Kui Wang
Journal:  J Clin Lab Anal       Date:  2016-09-30       Impact factor: 2.352

4.  Clinicopathological features and survival of gallbladder squamous cell carcinoma: analysis of 121 cases.

Authors:  Xiao-Ping Zou; Jie-Yu Wang; Yao-Ying Jiang; Gang Chen; Wei-Jia Mo; Zhen-Bo Feng
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

5.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

6.  Clinical correlation of calpain-1 and glypican-3 expression with gallbladder carcinoma.

Authors:  Weiqing Luo; Zhigang Ren; Sheng Gao; Hailong Jin; Geer Zhang; Lin Zhou; Shusen Zheng
Journal:  Oncol Lett       Date:  2016-01-07       Impact factor: 2.967

7.  Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy.

Authors:  Jae Woo Lee; Yong-Tae Kim; Sang Hyub Lee; Jun Hyuk Son; Jin Woo Kang; Ji Kon Ryu; Dong Kee Jang; Woo Hyun Paik; Ban Seok Lee
Journal:  Gut Liver       Date:  2018-01-15       Impact factor: 4.519

Review 8.  Novel biomarkers and endoscopic techniques for diagnosing pancreaticobiliary malignancy.

Authors:  Margaret G Keane; Amar Shah; Stephen P Pereira; Deepak Joshi
Journal:  F1000Res       Date:  2017-09-05

9.  Extracellular vesicle-shuttled miRNAs as a diagnostic and prognostic biomarker and their potential roles in gallbladder cancer patients.

Authors:  Eijiro Ueta; Koichiro Tsutsumi; Hironari Kato; Hiroshi Matsushita; Hidenori Shiraha; Masakuni Fujii; Kazuyuki Matsumoto; Shigeru Horiguchi; Hiroyuki Okada
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

10.  Prognostic significance of combined preoperative fibrinogen and CA199 in gallbladder cancer patients.

Authors:  Wei-Yu Xu; Hao-Hai Zhang; Xiao-Bo Yang; Yi Bai; Jian-Zhen Lin; Jun-Yu Long; Jian-Ping Xiong; Jun-Wei Zhang; Xin-Ting Sang; Hai-Tao Zhao
Journal:  World J Gastroenterol       Date:  2018-04-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.